547
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium

, , , &
Pages 596-605 | Accepted 28 Jan 2013, Published online: 04 Mar 2013

References

  • Hans G, Masquelier E, De Cock P. The diagnosis and management of neuropathic pain in daily practice in Belgium. An observational study. BMC Public Health 2007;7:170 doi:10.1186/1471-2458-7-170
  • Zelman DC, Dukes E, Brandenburg N, et al. Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. Pain 2005;115:29-36
  • Torrance N, Smith BH, Bennett MI, et al. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain, 2006;7:281-9
  • Bouhassira D, Lantéri-Minet M, Attal N et al. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136:380-97
  • Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-23
  • Annemans L, et al. Prospective assessment of the health and economic burden of neuropathic pain. Value Health, 2004;7:726
  • European Medicines Agency. European Public Assessment Report on pregabalin (EPAR). 10 April 2009. www.emea.europa.eu
  • Annemans L, Caekelbergh K, Morlion B, et al. A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain. Acta Clin Belg 2008;63:170-8
  • Thompson D. Toward a pharmacoeconomic model of neuropathic pain. Clin J Pain 2002;18:366-72
  • Van Seventer R, Feister HA, Young JP Jr, et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week randomized trial. Curr Res Med Opin 2006;22:375-84
  • Xochilcal-Morales M, Castro EM, Guajardo-Rosas J, et al. A prospective open-label, multicentre study of pregabalin in the treatment of neuropathic pain in Latin America. Int J Clin Pract 2010;64:1301-9
  • Gilron I, Wajsbrot D, Therrien F, et al. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. Clin J Pain 2011;27:185-93
  • Moon D, Lee D, Lee S, et al. Efficacy and tolerability of pregabalin using a flexible optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study. Clin Ther 2010;32:2370-85
  • Van Seventer R, Bach F, Toth C, et al. Pregabalin in the treatment of post-traumatic peripheral neuropathic pain: a randomized double-blind trial. Eur J Neurol 2010;17:1082-9
  • Stacey BR, Dworkin RH, Murphy K, et al. Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. Pain Med 2008;9;8;1202-8
  • Metropolis N, Ulam S. The Monte Carlo Method. J Am Stat Assoc 1949;44:335-41
  • Brazier J, Usherwood T, Harper R, et al. Deriving a preference-based single Index from the UK SF-36 Health Survey. J Clin Epidemiol 1998;51:1115-28
  • Cleemput I, Van Wilder P, Vrijens F, et al. Richtlijnen voor farmacoeconomische evaluaties in België. Health Technology Assessment (HTA). Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE); 2008. KCE Reports 78A (D/2008/10.273/23)
  • Towse A, Pritchard C, Devlin N. Cost-effectiveness thresholds: economic and ethical issues. King’s Funds/Office for Health Economics: London, 2002
  • Toth C. Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. Pain Med 2010;11:456-65
  • Hoffman D, Sadosky A, Alvir J. Cross-national burden of painful diabetic neuropathy in Asia, Latin America, and the Middle East. Pain Pract 2008;9:35-42
  • Aronoff GM. Evaluation and treatment of chronic pain. Pennsylvania: Williams & Wilkins, 1998
  • Tarride J, Gordon A, Vera-Llonch M, et al. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and post herpetic neuralgia. Clin Ther 2006;28;11;1922-34
  • Rodriguez M, Diaz S, Vera-Llonch M, et al. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin 2007;23;10;2585-96
  • Marchettini P, Da Deppo L, et al. Pregabalin versus gabapentin nel trattamento dei pazienti con neuropatia periferica: adattamento di un modello internazionale per la valutazione di costo/efficacia e costo/utilita all realta nazionale. Farmeconomia e percorsi therapeutici 2005;6:243-50
  • NICE – National Institute for Health and Clinical Excellence – Clinical Guideline 96 - Neuropathic pain-The pharmacological management of neuropathic pain in adults in non-specialist settings - March 2010

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.